FCMI
Foresite Capital Management IV Portfolio holdings
AUM
$124M
This Quarter Return
-14.31%
1 Year Return
-24.36%
3 Year Return
+1.86%
5 Year Return
+16.17%
10 Year Return
–
AUM
$357M
AUM Growth
+$357M
(-26%)
Cap. Flow
-$15.9M
Cap. Flow
% of AUM
-4.44%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
9
New
–
Increased
–
Reduced
3
Closed
–
Top Buys
No buys this quarter
Top Sells
| 1 |
Aclaris Therapeutics
ACRS
|
$8.62M |
| 2 |
HLTH
Cue Health Inc. Common Stock
HLTH
|
$4.79M |
| 3 |
Nurix Therapeutics
NRIX
|
$2.45M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
KNTE
1
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $109M | 30.47% | 9,671,643 | – | – |
|
2
Lyell Immunopharma
LYEL
$213M
| $67.1M | 18.77% | 13,282,181 | – | – |
|
3
Pharvaris
PHVS
$1.39B
| $59.2M | 16.55% | 3,261,926 | – | – |
|
|
4
Aclaris Therapeutics
ACRS
$209M
| $50M | 13.98% | 2,899,034 -500,000 | -15% | -$8.62M |
|
5
Kura Oncology
KURA
$686M
| $29.7M | 8.32% | 1,849,947 | – | – |
|
6
Quantum-Si Incorporated
QSI
$227M
| $20.9M | 5.84% | 4,463,619 | – | – |
|
|
7
Nurix Therapeutics
NRIX
$714M
| $14.4M | 4.04% | 1,030,798 -175,000 | -15% | -$2.45M |
|
|
CBAY
8
DELISTED
Cymabay Therapeutics
CBAY
| $5.56M | 1.55% | 1,787,094 | – | – |
|
|
HLTH
9
DELISTED
Cue Health Inc. Common Stock
HLTH
| $1.7M | 0.48% | 263,578 -742,511 | -74% | -$4.79M |
|